Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Titel:
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Auteur:
Zandberg, Dan P. Algazi, Alain P. Jimeno, Antonio Good, James S. Fayette, Jérôme Bouganim, Nathaniel Ready, Neal E. Clement, Paul M. Even, Caroline Jang, Raymond W. Wong, Stuart Keilholz, Ulrich Gilbert, Jill Fenton, Moon Braña, Irene Henry, Stephanie Remenar, Eva Papai, Zsuzsanna Siu, Lillian L. Jarkowski, Anthony Armstrong, Jon M. Asubonteng, Kobby Fan, Jean Melillo, Giovanni Mesía, Ricard